Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Atai Life Sciences launches Phase 1 clinical trial of MDMA derivative

By Brian Buntz | September 27, 2022

Atai Life SciencesA growing number of companies have launched clinical trials for methyl​enedioxy​methamphetamine (MDMA) and its derivatives.

The most recent is Atai Life Sciences, which saw its share price surge 7.71% in mid-day trading to $3.38 after announcing it had launched a Phase 1 study of an MDMA derivative, EMP-01. The study will focus on post-traumatic stress disorder (PTSD).

Last week, MindMed (Nasdaq: MNMD) announced that it had launched a Phase 1 study investigating MDMA-like substances in healthy volunteers.

Potential for PTSD and beyond

In 2020, Multidisciplinary Association for Psychedelic Studies (MAPS) completed a Phase 3 study of MDMA-assisted psychotherapy focused on PTSD. In addition, MAPS has Phase 2 studies underway for eating disorders, anxiety associated with a life-threatening illness and social anxiety in autism.

FDA has granted Breakthrough Therapy Designation to MAPS to test MDMA in PTSD.

Other companies investigating MDMA include Awakn Life Sciences Corp., which is testing its potential to treat addiction.

MDMA continues to be a Schedule I substance, which FDA classifies as having drugs “no currently accepted medical use” and “a high potential for abuse.” MAPS is advocating to have MDMA rescheduled as a Schedule III drug, which has “a ​​moderate to low potential for physical and psychological dependence.”

The patent for MDMA, initially filed by Merck in 1912, expired nearly a century ago.

MDMA derivatives, however, can be patented.

Atai’s study of the EMP-01 MDMA derivative

The Atai subsidiary EmpathBio will test the safety and tolerability of oral EMP-01 in 32 healthy volunteers.

According to Glenn Short, senior vice president, the company believes its MDMA derivative could have “a greater therapeutic index” than traditional MDMA, early development of Atai Life Sciences. “However, we are focused on refining MDMA’s entactogenic pharmacology to provide a greater therapeutic index. This study is a critical step towards ensuring that entactogen-assisted therapy is available to everyone who is struggling with PTSD.”

The company plans to use behavioral assessments, pharmacokinetics data and safety readouts to inform the design of Phase 2 clinical studies of EMP-01.

Currently, the only FDA-approved drugs for PTSD are the SSRIs paroxetine and sertraline.

“The need for new interventions for PTSD is critical given the current lack of effective treatments for those suffering from this debilitating mental health disorder,” said Florian Brand, CEO of Atai Life Sciences, in a statement. “We are thrilled to have received the necessary approvals for the initiation of the Phase 1 trial for EMP-01 to further progress the potential development of this promising new therapy.”


Filed Under: Psychiatric/psychotropic drugs
Tagged With: EMP-01, MindMed
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Why Cybin’s CEO sees RFK Jr. and J&J’s ketamine clinics as keys to clinical psilocybin’s mainstream moment
Muse Clinic: Innovating with Psychedelics and Neurotechnology
Can LSD break the 20-year drought in anxiety treatment?
MAPS
FDA rejection of MDMA and journal retractions jolt psychedelic therapy research
MDMA
Experts endorse MDMA-assisted therapy for PTSD amid FDA adcomm setback
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE